© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Author | Hans Minderman, PhD
Articles
Rational Design of Irinotecan Administration Based on Preclinical Models
August 01, 1998
Most clinical drug regimens for irinotecan (CPT-11 [Camptosar]) have been empirically based on classic in vivo pharmacokinetic and pharmacodynamic considerations. We propose an alternative approach that attempts to